SCHEMBL7563025

SCHEMBL7563025

OC(O)c1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.46
TDO2 P48775 2/20 0.46
AOC3 Q16853 1/20 0.45
HDAC3 O15379 1/20 0.44
HDAC4 P56524 1/20 0.44
HDAC1 Q13547 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC10 Q969S8 1/20 0.44
HDAC11 Q96DB2 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
HDAC9 Q9UKV0 1/20 0.44
HDAC5 Q9UQL6 1/20 0.44
KDM4E B2RXH2 1/20 0.39
ORAI1 Q96D31 1/20 0.39
ORAI2 Q96SN7 1/20 0.39
ORAI3 Q9BRQ5 1/20 0.39
TRPV6 Q9H1D0 1/20 0.39
CES2 O00748 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7079520 0.92 NR3C1 (0.42) IDO1TDO2AOC3HDAC3HDAC4
SCHEMBL2376299 0.83 ESR1 (0.35) KDM4EALDH1A1LMNASMN1; SMN2
SCHEMBL597442 0.81 IDO1 (0.46) IDO1TDO2AOC3HDAC3HDAC4
SCHEMBL11603843 0.81 IDO1 (0.46) IDO1TDO2AOC3HDAC3HDAC4
SCHEMBL4454516 0.79 IDO1 (0.44) IDO1TDO2AOC3HDAC3HDAC4
SCHEMBL1962791 0.77 AOC3 (0.47) IDO1TDO2AOC3HDAC3HDAC4
SCHEMBL20938211 0.77 IDO1 (0.48) IDO1TDO2AOC3HDAC3HDAC4
SCHEMBL13479485 0.77 IDO1 (0.48) IDO1TDO2AOC3HDAC3HDAC4
SCHEMBL502663 0.77 IDO1 (0.42) IDO1TDO2AOC3HDAC3HDAC4
SCHEMBL4551798 0.77 IDO1 (0.42) IDO1TDO2AOC3HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827642-B2 Compositions useful for treating disorders related to KIT BLUEPRINT MEDICINES CORPORATION (US) 2023-11-28 US disclosed
WO-2023215378-A1 METHODS OF TREATING FIBROSIS ATHIRA PHARMA, INC. (US) 2023-11-09 WO disclosed
US-20230167074-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF FUJIFILM CORPORATION (JP) 2023-06-01 US disclosed
US-20230167074-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF FUJIFILM CORPORATION (JP) 2023-06-01 US disclosed
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
US-20230129944-A1 COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT BLUEPRINT MEDICINES CORPORATION 2023-04-27 US disclosed
US-20210284645-A1 COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT BLUEPRINT MEDICINES CORPORATION (US) 2021-09-16 US disclosed
US-11040964-B2 Compounds and methods of use Ferro Therapeutics, Inc. (US) 2021-06-22 US disclosed
US-20200299283-A1 COMPOUNDS AND METHODS OF USE BRIDGEBIO PHARMA, INC. 2020-09-24 US disclosed
EP-2399584-A1 Boronic acids and esters as inhibitors of fatty acid amide hydrolase Infinity Pharmaceuticals, Inc. (US) 2011-12-28 EP disclosed
US-20020146633-A1 FLUORINATED AROMATIC ACETAL POLYMERS AND PHOTOSENSITIVE COMPOSITIONS CONTAINING SUCH POLYMERS KODAK POLYCHROME GRAPHICS L.L.C. 2002-10-10 US disclosed
US-6458503-B1 BLEND WITH DIAZO RESIN; LITHOGRAPHIC PRINTING PLATES; PHOTOPOLYMERIZATION AND CROSSLINKING KODAK POLYCHROME GRAPHICS LLC 2002-10-01 US disclosed
WO-2002073315-A1 FLUORINATED AROMATIC ACETAL POLYMERS AND PHOTOSENSITIVE COMPOSITIONS CONTAINING SUCH POLYMERS KODAK POLYCHROME GRAPHICS COMPANY, LTD. (US) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167074-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF, USE THEREOF, AND INTERMEDIATE THEREOF DHRS9, DHODH, CBR1 IDO1 446/4885TDO2 222/4885AOC3 522/4885
US-20200299283-A1 COMPOUNDS AND METHODS OF USE AIFM2, GPX4, GPX1 IDO1 3185/4885TDO2 4164/4885AOC3 1833/4885
US-11040964-B2 Compounds and methods of use AIFM2, GPX4, GPX1 IDO1 3185/4885TDO2 4164/4885AOC3 1833/4885
US-11827642-B2 Compositions useful for treating disorders related to KIT KIT, APC, MSH2 IDO1 4861/4885TDO2 4642/4885AOC3 4274/4885
US-20210284645-A1 COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT KIT, APC, MSH2 IDO1 4861/4885TDO2 4642/4885AOC3 4274/4885
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINE1, SERPINA3 IDO1 885/4885TDO2 3609/4885AOC3 1191/4885
US-20230129944-A1 COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT KIT, APC, MSH2 IDO1 4861/4885TDO2 4642/4885AOC3 4274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.